Our laboratory has previously reported that physiological levels of progestins stimulate growth of the human breast cancer cell line T47D. We have also determined that the antiprogestin RU486 inhibits this stimulation. Here we present the unexpected finding that RU486 alone also stimulates growth of these breast cancer cells. Thus, RU486 exhibits both antagonist and agonist-like activity, in a manner somewhat reminiscent of the antiestrogen tamoxifen. To our knowledge, this is the first report of stimulation of breast cancer growth by RU486.
No takes yet. Share an insight, caveat, or question.
BOWDEN et al. (1989) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: